XSTOICO
Market cap6mUSD
Dec 23, Last price
4.33SEK
1D
1.64%
1Q
-19.52%
IPO
-87.56%
Name
Iconovo AB
Chart & Performance
P/E
—
P/S
9.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.96%
Rev. gr., 5y
-9.88%
Revenues
7m
-58.65%
Net income
-46m
L-8.78%
CFO
-39m
L-11.67%
Earnings
Feb 17, 2025
Profile
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 7,078 -58.65% | 17,116 11.08% | 15,409 -13.39% | ||||||
Cost of revenue | (10,499) | 4,805 | 9,745 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 17,578 | 12,311 | 5,664 | ||||||
NOPBT Margin | 248.33% | 71.93% | 36.76% | ||||||
Operating Taxes | 2,147 | 5,452 | |||||||
Tax Rate | 17.44% | 96.26% | |||||||
NOPAT | 17,578 | 10,164 | 212 | ||||||
Net income | (45,894) -8.78% | (50,310) 92.31% | (26,161) 52.68% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 74,167 | 75,005 | |||||||
BB yield | -61.38% | -11.72% | |||||||
| Debt | |||||||||
Debt current | 2,818 | 2,332 | |||||||
Long-term debt | 12,632 | 17,730 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (3,030) | 6,615 | (95,037) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (38,603) | (43,704) | (11,013) | ||||||
CAPEX | (712) | (36,951) | (25,894) | ||||||
Cash from investing activities | (22,911) | (36,951) | (25,994) | ||||||
Cash from financing activities | 66,547 | (936) | 70,254 | ||||||
FCF | 16,327 | (4,954) | 7,216 | ||||||
| Balance | |||||||||
Cash | 18,480 | 13,446 | 94,937 | ||||||
Long term investments | 100 | ||||||||
Excess cash | 18,126 | 12,591 | 94,267 | ||||||
Stockholders' equity | (148,889) | (103,345) | (55,032) | ||||||
Invested Capital | 270,140 | 201,198 | 192,067 | ||||||
ROIC | 7.46% | 5.17% | 0.14% | ||||||
ROCE | 14.50% | 12.58% | 4.13% | ||||||
| EV | |||||||||
Common stock shares outstanding | 10,462 | 8,848 | 8,312 | ||||||
Price | 11.55 -76.43% | 49.00 -36.36% | 77.00 52.78% | ||||||
Market cap | 120,833 -72.13% | 433,528 -32.26% | 640,005 63.30% | ||||||
EV | 117,802 | 440,143 | 544,968 | ||||||
EBITDA | 35,509 | 19,252 | 6,922 | ||||||
EV/EBITDA | 3.32 | 22.86 | 78.72 | ||||||
Interest | 512 | 302 | |||||||
Interest/NOPBT | 2.91% | 2.46% | |||||||